Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Jan;105(1):71–76. doi: 10.1111/j.1476-5381.1992.tb14212.x

Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non-peptide antagonist.

F Feth 1, W Rascher 1, M C Michel 1
PMCID: PMC1908622  PMID: 1317738

Abstract

1. We have compared the binding and Ca2+ mobilizing properties of various full agonists, partial agonists and a non-peptide antagonist at the neuropeptide Y (NPY) receptor of human erythroleukemia (HEL) cells. 2. [125I]-NPY binding to intact HEL cells was rapid, saturable, of high affinity and with a specificity typical for the Y1-like subtype: NPY, peptide YY (PYY) and [Pro34]-NPY competed for [125I]-NPY binding with high affinity whereas NPY13-36 and NPY18-36 had only low affinity. 3. NPY, PYY and [Pro34]-NPY potently increased intracellular Ca2+ in HEL cells and had equal efficacy. NPY13-36, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP) increased intracellular Ca2+ only poorly. 4. Whereas VIP and PP did not significantly affect NPY-stimulated Ca2+ mobilization, NPY13-36 inhibited NPY-stimulated Ca2+ increases and shifted the NPY concentration-response curve to the right without altering its maximal effect. 5. The agonist (pEC50) potencies of the various peptides corresponded well with the affinities of these compounds in the binding assay (pKi), whereas the antagonist potencies (pKb) of the peptide partial agonists and the pA2 value of the non-peptide NPY antagonist (He 90481), calculated from functional data, were lower than the respective affinities determined in the binding studies. 6. A plot of the fractional Ca2+ response vs the fractional receptor occupancy did not reveal any non-linear receptor-effector coupling for NPY or [Pro34]-NPY; a small receptor reserve might exist for PYY. 7. We conclude that the binding and functional properties of HEL cell NPY receptors are very similar.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balasubramaniam A., Sheriff S. Neuropeptide Y (18-36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes. J Biol Chem. 1990 Sep 5;265(25):14724–14727. [PubMed] [Google Scholar]
  2. Boublik J. H., Scott N. A., Brown M. R., Rivier J. E. Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions. J Med Chem. 1989 Mar;32(3):597–601. doi: 10.1021/jm00123a014. [DOI] [PubMed] [Google Scholar]
  3. Chang R. S., Lotti V. J., Chen T. B. Specific [3H]propionyl-neuropeptide Y (NPY) binding in rabbit aortic membranes: comparisons with binding in rat brain and biological responses in rat vas deferens. Biochem Biophys Res Commun. 1988 Mar 30;151(3):1213–1219. doi: 10.1016/s0006-291x(88)80495-9. [DOI] [PubMed] [Google Scholar]
  4. Danho W., Triscari J., Vincent G., Nakajima T., Taylor J., Kaiser E. T. Synthesis and biological evaluation of pNPY fragments. Int J Pept Protein Res. 1988 Dec;32(6):496–505. doi: 10.1111/j.1399-3011.1988.tb01380.x. [DOI] [PubMed] [Google Scholar]
  5. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984 Apr;8(3):225–235. doi: 10.1016/0167-0115(84)90064-8. [DOI] [PubMed] [Google Scholar]
  6. Feth F., Rascher W., Michel M. C. G-protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):1–7. doi: 10.1007/BF00167376. [DOI] [PubMed] [Google Scholar]
  7. Gray T. S., Morley J. E. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. Life Sci. 1986 Feb 3;38(5):389–401. doi: 10.1016/0024-3205(86)90061-5. [DOI] [PubMed] [Google Scholar]
  8. Krstenansky J. L., Owen T. J., Payne M. H., Shatzer S. A., Buck S. H. C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor. Neuropeptides. 1990 Nov;17(3):117–120. doi: 10.1016/0143-4179(90)90073-8. [DOI] [PubMed] [Google Scholar]
  9. Laduron P. M. Criteria for receptor sites in binding studies. Biochem Pharmacol. 1984 Mar 15;33(6):833–839. doi: 10.1016/0006-2952(84)90436-2. [DOI] [PubMed] [Google Scholar]
  10. Lundberg J. M., Hemsén A., Larsson O., Rudehill A., Saria A., Fredholm B. B. Neuropeptide Y receptor in pig spleen: binding characteristics, reduction of cyclic AMP formation and calcium antagonist inhibition of vasoconstriction. Eur J Pharmacol. 1988 Jan 5;145(1):21–29. doi: 10.1016/0014-2999(88)90344-5. [DOI] [PubMed] [Google Scholar]
  11. Martel J. C., Fournier A., St-Pierre S., Dumont Y., Forest M., Quirion R. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors. Mol Pharmacol. 1990 Oct;38(4):494–502. [PubMed] [Google Scholar]
  12. McKernan R. M., Howard M. J., Motulsky H. J., Insel P. A. Compartmentation of alpha 2-adrenergic receptors in human erythroleukemia (HEL) cells. Mol Pharmacol. 1987 Aug;32(1):258–265. [PubMed] [Google Scholar]
  13. Michel M. C., Brass L. F., Williams A., Bokoch G. M., LaMorte V. J., Motulsky H. J. Alpha 2-adrenergic receptor stimulation mobilizes intracellular Ca2+ in human erythroleukemia cells. J Biol Chem. 1989 Mar 25;264(9):4986–4991. [PubMed] [Google Scholar]
  14. Michel M. C. Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. Trends Pharmacol Sci. 1991 Oct;12(10):389–394. doi: 10.1016/0165-6147(91)90610-5. [DOI] [PubMed] [Google Scholar]
  15. Michel M. C., Schlicker E., Fink K., Boublik J. H., Göthert M., Willette R. N., Daly R. N., Hieble J. P., Rivier J. E., Motulsky H. J. Distinction of NPY receptors in vitro and in vivo. I. NPY-(18-36) discriminates NPY receptor subtypes in vitro. Am J Physiol. 1990 Jul;259(1 Pt 1):E131–E139. doi: 10.1152/ajpendo.1990.259.1.E131. [DOI] [PubMed] [Google Scholar]
  16. Motulsky H. J., Michel M. C. Interaction between alpha 2-adrenergic and NPY receptor pathways in human erythroleukemia cells. Clin Exp Hypertens A. 1989;11 (Suppl 1):281–286. doi: 10.3109/10641968909045432. [DOI] [PubMed] [Google Scholar]
  17. Motulsky H. J., Michel M. C. Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am J Physiol. 1988 Dec;255(6 Pt 1):E880–E885. doi: 10.1152/ajpendo.1988.255.6.E880. [DOI] [PubMed] [Google Scholar]
  18. Potter E. K. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther. 1988;37(2):251–273. doi: 10.1016/0163-7258(88)90028-9. [DOI] [PubMed] [Google Scholar]
  19. Servin A. L., Rouyer-Fessard C., Balasubramaniam A., Saint Pierre S., Laburthe M. Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors. Endocrinology. 1989 Feb;124(2):692–700. doi: 10.1210/endo-124-2-692. [DOI] [PubMed] [Google Scholar]
  20. Sheikh S. P., O'Hare M. M., Tortora O., Schwartz T. W. Binding of monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cell lines. J Biol Chem. 1989 Apr 25;264(12):6648–6654. [PubMed] [Google Scholar]
  21. Tatemoto K. Neuropeptide Y and its receptor antagonists. Use of an analog mixture-screening strategy. Ann N Y Acad Sci. 1990;611:1–6. doi: 10.1111/j.1749-6632.1990.tb48917.x. [DOI] [PubMed] [Google Scholar]
  22. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5485–5489. doi: 10.1073/pnas.79.18.5485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Thomsen W. J., Jacquez J. A., Neubig R. R. Inhibition of adenylate cyclase is mediated by the high affinity conformation of the alpha 2-adrenergic receptor. Mol Pharmacol. 1988 Dec;34(6):814–822. [PubMed] [Google Scholar]
  24. Wahlestedt C., Yanaihara N., Håkanson R. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept. 1986 Feb;13(3-4):307–318. doi: 10.1016/0167-0115(86)90048-0. [DOI] [PubMed] [Google Scholar]
  25. Walker M. W., Miller R. J. 125I-neuropeptide Y and 125I-peptide YY bind to multiple receptor sites in rat brain. Mol Pharmacol. 1988 Dec;34(6):779–792. [PubMed] [Google Scholar]
  26. Walker P., Grouzmann E., Burnier M., Waeber B. The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci. 1991 Mar;12(3):111–115. doi: 10.1016/0165-6147(91)90518-w. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES